If your insurance won’t cover Wegovy, you have real options: appeal the denial, request a formulary exception, escalate to an independent external review, use the manufacturer’s savings card or patient assistance program, and cover out-of-pocket costs with an HSA, FSA, or medical expense deduction. Which path fits you depends on the type of plan you have and the reason the insurer said no. Wegovy runs roughly $1,350 per month at list price, so the stakes are high enough to work through the process carefully.
Figure Out Why the Denial Happened
Before you do anything else, get the formal denial letter and read the reason. Insurers deny Wegovy for a handful of predictable reasons, and each one calls for a different response.
The most common is straightforward formulary exclusion. Many ACA marketplace plans and employer-sponsored plans don’t cover GLP-1 drugs approved for obesity at all. If the drug is excluded from the formulary entirely, an ordinary appeal on medical-necessity grounds isn’t the right tool; a formulary exception request is.
The second common reason is that the insurer decided you don’t meet its clinical criteria. Wegovy’s FDA-approved labeling covers adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. Insurers that do cover Wegovy generally track those thresholds, though some require a BMI above 30 regardless of comorbidities, and nearly all require documented participation in a lifestyle program combining a reduced-calorie diet with increased physical activity.
The third is step therapy. Your plan may require you to try and fail on cheaper alternatives like Contrave, Saxenda, Qsymia, or Xenical before it will authorize Wegovy. If that’s the reason, your appeal needs specific dates, dosages, and reasons each alternative didn’t work or caused side effects.
Which of these applies dictates what evidence you need to send back.
File an Internal Appeal
You have 180 days from the date you receive the denial notice to file an internal appeal, and this step is worth taking seriously.1HealthCare.gov. Appealing a Health Plan Decision: Internal Appeals Many denials get overturned once the reviewer sees clinical documentation the first decision lacked.
The single most important piece of the appeal is a letter of medical necessity from your prescribing physician. A vague letter saying the patient needs the drug will not move a reviewer. A useful letter includes baseline height, weight, and BMI drawn from chart notes; documented weight-related conditions like type 2 diabetes, hypertension, obstructive sleep apnea, or cardiovascular disease with supporting lab work; a history of structured lifestyle modification with real evidence (dietary logs, gym receipts, wearable data); a list of every prior weight-loss medication tried, with dates and the reason each was ineffective or caused adverse effects; and a specific clinical explanation of why formulary alternatives will not work for you. If you have cardiovascular disease, peripheral arterial disease, prediabetes, or a liver condition like metabolic dysfunction-associated steatohepatitis, the letter should document those diagnoses with test results attached. Detail is what makes a denial hard to uphold.
When You Need a Faster Answer
If waiting the standard timeline would seriously jeopardize your health, request an expedited review. A final decision on an expedited internal appeal must come as quickly as your medical condition requires, and no later than 72 hours after the insurer receives the request. You can also file for external review at the same time you submit an expedited internal appeal, rather than finishing one before starting the other.1HealthCare.gov. Appealing a Health Plan Decision: Internal Appeals
Request a Formulary Exception if the Drug Is Excluded
When Wegovy simply isn’t on your plan’s formulary, the right tool is a formulary exception request. It asks the insurer to make a one-time coverage decision for a drug it doesn’t normally cover.
For Medicare Part D, your prescriber must submit a supporting statement explaining that every drug on the plan’s formulary would either be less effective for your condition or cause you adverse effects. The statement can be verbal or written, though the plan may require a written follow-up. Once the plan has the prescriber’s statement, it must issue a decision within 72 hours for standard requests or 24 hours for expedited requests.2CMS. Exceptions
Commercial plans run their own exception processes, described in your summary of benefits or member handbook. The strategy is the same: your doctor makes the case that nothing on the formulary works for you specifically.
Escalate to External Review
If the insurer upholds the denial after your internal appeal, request an external review. Your case goes to an independent review organization with no financial ties to the insurer, and the reviewer evaluates the denial against applicable laws, the plan’s own terms, and accepted medical standards.3HHS.gov. Internal Claims and Appeals and the External Review Process Overview The decision binds the insurer.
External review covers denials based on medical necessity, appropriateness, health care setting, level of care, and the effectiveness of a covered benefit. A final decision must come within 72 hours for expedited requests or within 45 days for standard requests.4CMS. How to Appeal a Decision About Your Health Insurance
Under the federal external review process, no filing fee can be charged. State-run processes may charge a nominal fee of up to $25, refundable if the decision goes your way, waived for financial hardship, and capped at $75 per claimant per plan year.5eCFR. 45 CFR 147.136 – Internal Claims and Appeals and External Review Processes
If You Have Medicare
Medicare’s relationship with Wegovy is complicated. Federal law has historically excluded weight-loss drugs from Part D coverage. The statutory definition of a covered Part D drug at Section 1860D-2(e)(2) of the Social Security Act specifically carves out agents used for weight loss.6ASPE. Medicare Coverage of Anti-Obesity Medications Two developments have opened doors around that exclusion.
Cardiovascular Indication
In March 2024, the FDA approved Wegovy for a second indication: reducing the risk of heart attack, stroke, and cardiovascular death in adults with established cardiovascular disease who also have obesity or are overweight.7FDA. FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults With Obesity or Overweight Because that use treats cardiovascular disease rather than obesity itself, it falls outside the weight-loss exclusion. Part D plans can and do cover Wegovy when prescribed to reduce cardiovascular risk, using the standard formulary exception process if needed.8CMS. Medicare GLP-1 Bridge If you have a history of heart attack, stroke, or other established cardiovascular disease, ask your doctor to prescribe under this indication and document the cardiovascular basis on the prior authorization paperwork.
The 2026 GLP-1 Bridge Demonstration
For Medicare beneficiaries who need Wegovy for weight management and don’t qualify under the cardiovascular indication, a new option arrives in mid-2026. The Medicare GLP-1 Bridge demonstration runs July 1 through December 31, 2026, and covers Wegovy for weight reduction nationwide. Eligibility requires enrollment in a standalone Part D plan or a Medicare Advantage plan with drug coverage; Special Needs Plans and employer/union group waiver plans are also included. The clinical thresholds are tighter than the standard FDA label, running from a BMI of 27 with certain conditions (prediabetes, prior heart attack or stroke, peripheral arterial disease, and others) up to a BMI of 35 with no additional condition required.8CMS. Medicare GLP-1 Bridge It’s a six-month window, so acting quickly once enrollment opens matters.
If You Have Medicaid
Federal Medicaid law lets states decide whether to cover weight-loss drugs.9Office of the Law Revision Counsel. 42 US Code 1396r-8 – Payment for Covered Outpatient Drugs GLP-1 drugs prescribed solely for obesity remain optional. As of early 2026, roughly 13 to 16 state Medicaid programs covered GLP-1 medications for obesity, with that number slowly growing. A Biden-era proposal to require all state Medicaid programs to cover anti-obesity drugs was not carried forward by the Trump administration.
Even in a state that excludes obesity coverage, Medicaid may still cover Wegovy when prescribed for an indication the program must cover, such as type 2 diabetes management or cardiovascular risk reduction. Check with your state Medicaid office or managed care plan, and make sure your prescriber documents the covered indication on any prior authorization forms.
If You’re in a Self-Funded Employer Plan
Some states require insurers to cover obesity treatments, including prescription medications. The mandates vary: some cover only state employee plans, others reach individual and small-group markets, and a few define obesity as a chronic disease and require coverage of FDA-approved treatments with medical justification.
Here’s the boundary that catches many people: employer-sponsored plans that self-fund their health benefits are regulated under the federal Employee Retirement Income Security Act, not state insurance law.10U.S. Department of Labor. ERISA ERISA preempts state insurance mandates, so a self-funded plan in a state that requires obesity drug coverage can still exclude Wegovy. Most large employers self-fund. If you work for a large company and your plan excludes weight-management drugs, a state mandate probably doesn’t help, but raising the issue with your employer’s benefits department can. Self-funded employers choose their own coverage, and some have added GLP-1 coverage in response to employee demand at renewal.
Cut the Cost With Manufacturer Programs
While you work the appeals process, or if you decide to pay out of pocket, Novo Nordisk offers two programs that materially change the price.
Savings Card
If you have commercial insurance that covers Wegovy, the manufacturer’s savings card can bring your copay down to as little as $25 per month, with savings of up to $100 per one-month fill. If your commercial plan doesn’t cover Wegovy, or you fill outside your insurance, the savings card sets a self-pay price of $349 per month for the injection. New patients who haven’t used a Wegovy savings offer in the past year may qualify for an introductory price of $199 per month on the 0.25 mg and 0.5 mg starter doses for the first two fills. Wegovy is now also available as an oral tablet, with savings card pricing of $149 to $299 per month depending on strength.11NovoCare. Wegovy Savings Offer Terms and Conditions
The savings card is not available to anyone enrolled in a federal or state healthcare program, including Medicare, Medicaid, TRICARE, or VA benefits. Even if you have Medicare and want to pay cash, you cannot use the card.
Patient Assistance Program
Novo Nordisk’s Patient Assistance Program provides Wegovy at no cost to eligible patients. You must be a U.S. citizen or legal resident, have no insurance coverage for the medication, and have a household income at or below a qualifying threshold tied to the federal poverty level. For most Novo Nordisk medications, the income limit is 400% of the federal poverty level, though some products differ.12NovoCare. Patient Assistance Program (PAP) The application requires documentation of income and insurance status.
Use an HSA, FSA, or Medical Deduction if You’re Paying Out of Pocket
Tax-advantaged accounts can soften the cost. Both HSAs and FSAs can reimburse prescription weight-loss medication when the drug treats a specific diagnosed condition like obesity, type 2 diabetes, or cardiovascular disease. Your administrator may ask for a letter of medical necessity from your doctor explaining the diagnosis. Keep receipts and the letter on file in case of audit.
For 2026, the HSA contribution limit is $4,400 for self-only coverage and $8,750 for family coverage.13Internal Revenue Service. Rev Proc 2025-19 The health care FSA contribution limit is $3,400. At the $349 monthly self-pay injection price, an annual cost of roughly $4,200 would consume nearly an entire individual HSA contribution, so plan accordingly during open enrollment.
You can also deduct prescription weight-loss medication costs as an itemized medical expense, but only the amount above 7.5% of your adjusted gross income, and only when the medication is prescribed to treat a specific disease diagnosed by a physician (such as obesity or heart disease). Costs for general wellness or appearance don’t qualify.14Internal Revenue Service. Topic No 502, Medical and Dental Expenses The 7.5% floor means the deduction only helps if your total medical spending for the year is substantial.
Where Else to Complain
If both the internal appeal and external review fail, a few more channels remain, and which one fits depends on your plan.
For individual and small-group plans regulated by your state, file a complaint with your state insurance department. Most have consumer assistance programs that investigate whether a denial violates state law or the terms of your policy. Some states also run ombudsman programs that mediate disputes without formal legal action.
For employer-sponsored plans governed by ERISA, complaints go to the U.S. Department of Labor’s Employee Benefits Security Administration, which can review whether the insurer properly applied the plan’s own terms. EBSA’s benefits advisors can be reached at 1-866-444-3272.15U.S. Department of Labor. Filing a Claim for Your Health Benefits A lawsuit is technically available if administrative remedies are exhausted, but the cost and time make it impractical for most prescription drug disputes.
One quiet lever that doesn’t involve any agency: if you’re in a self-funded employer plan, take the issue directly to HR or benefits. Employers designing self-funded plans choose what to cover, and persistent employee requests have prompted some companies to add GLP-1 coverage at their next annual renewal. It’s slower than an appeal, but often more effective than fighting the same denial year after year.